Tyra Biosciences Inc. (TYRA)
12.79
0.00 (0.00%)
At close: Feb 20, 2025, 3:59 PM
12.78
-0.12%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 12.12 |
| Market Cap | 676.50M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.61 |
| PE Ratio (ttm) | -7.95 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 14.5 |
| Volume | 112,382 |
| Avg. Volume (20D) | 239,220 |
| Open | 12.84 |
| Previous Close | 12.79 |
| Day's Range | 12.63 - 12.88 |
| 52-Week Range | 11.88 - 29.60 |
| Beta | undefined |
About TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondro...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2021
Employees 49
Stock Exchange NASDAQ
Ticker Symbol TYRA
Website https://www.tyra.bio
Analyst Forecast
According to 6 analyst ratings, the average rating for TYRA stock is "Buy." The 12-month stock price forecast is $30.5, which is an increase of 138.37% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
-23.35%
Tyra Biosciences shares are trading lower. The com...
Unlock content with
Pro Subscription
